After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …

The emergence of the novel coronavirus disease known as COVID-19 creates another
health burden for people living with HIV (PLWH) who face multiple morbidities and may be …

Messenger RNA (mRNA) vaccines against COVID‐19 are the first authorized biological
preparations developed using this platform. During the pandemic, their administration has …

Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing
antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of …

Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the
HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the …

Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

Antibody responses to the HIV-1 envelope glycoproteins can be classified into three groups.
Binding but non-neutralizing responses are directed to epitopes that are expressed on …

Antibodies serve as critical barriers to viral infection. Humoral immunity to a virus is achieved
through the dual role of antibodies in communicating the presence of invading pathogens in …

Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …